The estimated Net Worth of Stephen W Potter is at least $520 Thousand dollars as of 30 June 2022. Mr Potter owns over 8,070 units of Applied Genetic Technologies Corp stock worth over $21,794 and over the last 10 years he sold AGTC stock worth over $6,214. In addition, he makes $492,172 as VP & Chief Bus. Officer at Applied Genetic Technologies Corp.
Mr has made over 2 trades of the Applied Genetic Technologies Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 8,070 units of AGTC stock worth $6,214 on 30 June 2022.
The largest trade he's ever made was selling 8,070 units of Applied Genetic Technologies Corp stock on 30 June 2022 worth over $6,214. On average, Mr trades about 592 units every 132 days since 2015. As of 30 June 2022 he still owns at least 55,883 units of Applied Genetic Technologies Corp stock.
You can see the complete history of Mr Potter stock trades at the bottom of the page.
Stephen W. Potter is the VP & Chief Bus. Officer at Applied Genetic Technologies Corp.
As the VP & Chief Bus. Officer of Applied Genetic Technologies Corp, the total compensation of Mr Potter at Applied Genetic Technologies Corp is $492,172. There are 1 executives at Applied Genetic Technologies Corp getting paid more, with Susan B. Washer having the highest compensation of $788,551.
Mr Potter is 65, he's been the VP & Chief Bus. Officer of Applied Genetic Technologies Corp since . There are no older and 2 younger executives at Applied Genetic Technologies Corp.
Stephen's mailing address filed with the SEC is C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE #10, ALACHUA, FL, 32615.
Over the last 11 years, insiders at Applied Genetic Technologies Corp have traded over $12,578,298 worth of Applied Genetic Technologies Corp stock and bought 760,946 units worth $8,946,827 . The most active insiders traders include Plc Gsk, Edward Hurwitz, and Ventures, Inc. Med Immune. On average, Applied Genetic Technologies Corp executives and independent directors trade stock every 89 days with the average trade being worth of $18,318. The most recent stock trade was executed by Stephen W Potter on 30 June 2022, trading 8,070 units of AGTC stock currently worth $6,214.
Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.
Applied Genetic Technologies Corp executives and other stock owners filed with the SEC include: